Eli Lilly’s triple-hormone agonist retatrutide (LY3437943) has crossed a quiet but consequential line. The registry record for TRIUMPH-1 — the company’s flagship Phase 3 obesity trial — now reads overallStatus: COMPLETED, with the change posted to ClinicalTrials.gov on June 3, 2026. What it does not yet contain is a single efficacy number.
TRIUMPH-1 (NCT05929066) is a randomized, double-blind, placebo-controlled trial that enrolled an actual 2,335 participants who have obesity or overweight, without type 2 diabetes. Patients were assigned to one of three subcutaneous retatrutide doses or to placebo, with the primary endpoint defined as percent change from baseline in body weight at Week 80. The registry lists an actual primary completion date of April 6, 2026 and an overall completion date of April 30, 2026.
What “completed” does and doesn’t tell us
A completed status confirms the protocol ran to its planned end and follow-up has closed — not that the drug worked. The registry’s results module remains empty (hasResults: false), so the magnitude of weight loss, the placebo comparison, the confidence intervals, and the safety profile are all still unreported here.
The status flag tells you the trial is over. It tells you nothing yet about the effect size.
Retatrutide targets the GLP-1, GIP and glucagon receptors, a mechanism that drew attention after earlier-phase data. TRIUMPH-1 also embedded sub-studies in knee osteoarthritis and obstructive sleep apnea, with condition-specific secondary measures. Until Lilly posts registry results or a peer-reviewed readout, those endpoints — primary and secondary alike — remain unquantified. This desk will report the numbers when they are public, not before.